PHENOBARBITONE TABLET 60mg

Product Information

Registration Status: Active

PHENOBARBITONE TABLET 60mg is approved to be sold in Singapore with effective from 1989-06-10. It is marketed by DRUG HOUSES OF AUSTRALIA PTE LTD, with the registration number of SIN03709P.

This product contains Phenobarbitone 60mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by PT ACTAVIS INDONESIA in INDONESIA REP OF.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Phenobarbitone

Description

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. [PubChem]

Indication

For the treatment of all types of seizures except absence seizures.

Mechanism of Action

Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.

Pharmacokinetics

Absorption
Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.
Distribution
Metabolism
Hepatic (mostly via CYP2C19).
Elimination

Toxicity

CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.

Active Ingredient/Synonyms

5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione | 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione | 5-Ethyl-5-phenylbarbituric acid | 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione | 5-Phenyl-5-ethylbarbituric acid | Phenobarbital | Phenobarbitol | Phenobarbitone | Phenobarbituric Acid | Phenylaethylbarbitursaeure | Phenylethylbarbiturate | Phenylethylbarbituric Acid | Phenylethylbarbitursaeure | PHENYLETHYLMALONYLUREA | Phenobarbital |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank